Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Josep Tabernero1, Malvika Vyas2, Rosa Giuliani3, Dirk Arnold4, Fatima Cardoso5, Paolo G. Casali6, Andres Cervantes7, Alexander M.M. Eggermont8, Alexandru Eniu9, Jacek Jassem10, George Pentheroudakis11, Solange Peters12, Stefan Rauh13, Christoph C. Zielinski14, Rolf A. Stahel15, Emile Voest16, Jean-Yves Douillard2, Keith McGregor2, Fortunato Ciardiello17
1Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona,
2European Society for Medical Oncology
3Medical Oncology, San Camillo-Forlanini Hospital,
4Cancer Center, CUF Hospitals,
5Breast Unit, Champalimaud Clinical Center,
6Fondazione IRCCS National Cancer Institute,
7Hematology-Medical Oncology Department, Clinic Hospital,
8Gustave Roussy Cancer Campus Grand Paris,
9Department of Breast Tumors, Cancer Institute “Ion Chiricuta”,
10Department of Oncology and Radiotherapy, Medical University of Gdansk,
11University of Ioannina
12Oncology Department, Centre Hospitalier Universitaire Vaudois,
13Department of Hemato-oncology, Hospital Center Emile Mayrisch,
14Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna,
15Netherlands Cancer Institute
16University Hospital Zürich
17Second University of Naples,